ERIS

Eris Lifesciences Share Price

 

 

Invest in Eris Lifesciences with 3.32X leverage

Invest with MTF

Performance

  • Low
  • ₹1,512
  • High
  • ₹1,556
  • 52 Week Low
  • ₹1,097
  • 52 Week High
  • ₹1,910
  • Open Price₹1,553
  • Previous Close₹1,545
  • Volume56,045

Investment Returns

  • Over 1 Month -7.64%
  • Over 3 Month -6.16%
  • Over 6 Month -6.27%
  • Over 1 Year + 13.68%

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 50
  • PEG Ratio
  • 2.6
  • Market Cap Cr
  • 20,785
  • P/B Ratio
  • 6.7
  • Average True Range
  • 41.95
  • EPS
  • 30.52
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -9.37
  • RSI
  • 43.76
  • MFI
  • 81.86

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,525.90
-19.1 (-1.24%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,576.02
  • 50 Day
  • ₹1,596.31
  • 100 Day
  • ₹1,609.01
  • 200 Day
  • ₹1,563.68

Resistance and Support

1550.17 Pivot Speed
  • R3 1,579.83
  • R2 1,571.67
  • R1 1,558.33
  • S1 1,536.83
  • S2 1,528.67
  • S3 1,515.33

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,998.16 Cr. on a trailing 12-month basis. An annual revenue growth of 43% is outstanding, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a debt to equity of 61%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-24 Preferential issue of shares Inter-alia, To consider the protposal of issuance ofequity shares of the Company by way of a preferential issue for consideration other than cash.. per share(601%)Interim Dividend
2025-11-12 Quarterly Results
2025-08-05 Quarterly Results
2025-05-19 Audited Results
2025-02-07 Interim Dividend
Date Purpose Remarks
2025-02-13 INTERIM Rs.7.35 per share(735%)Interim Dividend
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend
View Eris Lifesciences Dividend History Arrow

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.85%
17.33%
1.2%
7.21%
0%
9.12%
10.29%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,525 As on 26 December, 2025 | 15:38

The Market Cap of Eris Lifesciences is ₹20785.3 Cr As on 26 December, 2025 | 15:38

The P/E ratio of Eris Lifesciences is 50 As on 26 December, 2025 | 15:38

The PB ratio of Eris Lifesciences is 6.7 As on 26 December, 2025 | 15:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23